The United States Food and Drug Administration (FDA) is making an effort to educate patients/prescribers and ensure better communication for the potential risks of opioid use. FDA Commissioner stated “Opioid addiction and overdose have reached epidemic levels over the past decade, and the FDA remains steadfast in our commitment to do our part to help reverse the devastating impact of the misuse and abuse of prescription opioids.”
In a continuing effort, the FDA recently announced requirements for safety labeling changes for opioid pain medications.
This conference is intended to discuss new labeling changes and FDA recommendations applicable for opioid pain medications. It is further intended to present FDA pending actions for the opioid industry to stay compliant with the FDA recommendations and requirements. Join expert speaker David Lim, who through this presentation will provide great opportunities to become aware of and get familiar with FDA’s new requirements for opioid labeling changes. In this conference, David will discuss what firms should consider and implement the good practices compliant with the FDA’s recommendations so that FDA enforcement actions can be avoided.
Who should attend?
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Consulting Firm, Regulatory Doctor (www.RegulatoryDoctor.us). As a leading industry speaker, Dr. Lim frequently presents various topics in areas of FDA regulatory, clinical, quality and regulatory compliance matters in various forums and meetings.